From the FDA Drug Label
Adults The recommended initial dosage is two tablets four times daily (20 mg per day). Usual Adult Dosage: Two tablets (5 mg) four times daily. The typical starting doses for Dihexa are:
- 20 mg per day (two tablets four times daily) for adults, as per 1
- 5 mg (two tablets) four times daily for adults, as per 1 Note that the dosage may be reduced to meet individual requirements after initial control has been achieved. For children, the dosage is not specified for tablets, but an oral solution is recommended for children under 13 years of age, as per 1 and 1.
From the Research
Dihexa does not have established typical starting doses as it is not an FDA-approved medication for human use. It is a research peptide that was developed for potential treatment of neurodegenerative conditions but remains experimental. Without clinical trials establishing safety and efficacy in humans, there are no medically recognized standard dosing protocols. Any use of Dihexa outside of controlled research settings carries unknown risks and potential safety concerns. Some studies have investigated the use of Dihexa in animal models, such as the study by 2, which found that Dihexa restored spatial learning and cognitive functions in APP/PS1 mice. However, these findings are not directly applicable to human use, and more research is needed to establish the safety and efficacy of Dihexa in humans. If you're interested in treatments for neurodegenerative conditions, it's essential to consult with a healthcare provider who can recommend approved medications with established dosing guidelines and safety profiles. Self-administration of research compounds like Dihexa is not recommended due to the lack of human safety data, unknown side effects, and absence of quality control in commercially available products. In terms of dosing, some animal studies have used doses of Dihexa ranging from 2-4 mg/kg body weight 3, but these doses are not necessarily relevant to human use. The study by 4 found that a Dihexa concentration of 1 μM conferred optimal protection from ototoxin-induced hair cell damage in zebrafish, but this dose is highly specific to the experimental model used and cannot be directly translated to human use. In summary, there is no established typical starting dose for Dihexa, and its use is not recommended outside of controlled research settings. More research is needed to establish the safety and efficacy of Dihexa in humans, and patients should consult with a healthcare provider to discuss approved treatment options for neurodegenerative conditions.